On ECHEMI
Home > Drugs > Compound fluorouracil oral solution

Compound fluorouracil oral solution

Function and Efficacy

This product is first converted into 5-fluoro-2-deoxyuridine nucleotide in the body, which inhibits thymine nucleotide synthetase, blocking the conversion of deoxyuridine nucleotide into deoxythymine nucleotide, thereby inhibiting the biosynthesis of DNA. In addition, it can also be incorporated into RNA, and inhibit RNA synthesis by preventing uracil and orotic acid from incorporating into RNA. This product is a cell cycle-specific drug, mainly inhibiting S-phase tumor cells. Oleic acid has a synergistic effect with fluorouracil in the prescription. Ginseng polysaccharide, as an immunostimulant, has a promoting effect on the body's immune function and prevents the toxic and side effects of fluorouracil on the body.

Ingredients

It is an oral solution mainly made of fluorouracil and ginseng polysaccharide. The fluorouracil (C4H3FN2O2) content should be 90.0% to 110.0% of the labeled amount. The prescription is 4g of fluorouracil, 8g of ginseng polysaccharide, 20g of soybean lecithin, and an appropriate amount of water, a total of 1000ml.

Name Description Content CAS NO. Manufacturer
5-FluorouracilIngredients

It is first converted into 5-fluoro-2-deoxyuridine nucleotide in the body, which inhibits thymidine nucleotide synthetase, blocking the conversion of deoxyuridine nucleotide into deoxythymidine nucleotide, thereby inhibiting DNA biosynthesis. In addition, it can also be incorporated into RNA, inhibiting RNA synthesis by preventing uracil and orotic acid from incorporating into RNA. It is a cell cycle-specific drug that mainly inhibits S-phase tumor cells.

More
51-21-8 21

Indication

Used for the treatment of digestive tract cancer (colon cancer, rectal cancer, gastric cancer), breast cancer, primary liver cancer and other cancers.

Usage and Dosage

Oral administration. Adults, 1 tablet at a time, 2 times a day.

Adverse Reactions

1. This product has significant toxic and side effects. Nausea, loss of appetite or vomiting, usually not serious at the dose, oral mucosal inflammation or ulcers, abdominal discomfort or diarrhea are occasionally seen. Peripheral blood leukopenia is common (mostly reaches the lowest point within 2 to 3 weeks after the start of the treatment, and returns to normal after about 3 to 4 weeks), thrombocytopenia is rare. Cough, shortness of breath or cerebellar ataxia are extremely rare. 2. Long-term use can lead to nervous system toxicity and bone marrow suppression. 3. Occasionally myocardial ischemia after medication, angina pectoris and electrocardiogram changes may occur.

Precautions

Due to the risk of sudden death, patients with cardiovascular reactions (arrhythmia, angina pectoris, ST segment changes) are contraindicated.

Special Population Medication

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

Drug Interactions

Drug interactions may occur if used with other drugs. Please consult your doctor or pharmacist for details.

Storage

Seal and store in a dark place.

Packaging Specification

0.4% (fluorouracil)

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.